SELLAS Life Sciences Group, Inc. (SLS)
Nasdaq · Healthcare · Biotechnology
$11.63−0.94%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.3B
- 52-week range
- $1.39 – $15.88
- 52-week change
- +512.11%
- EPS (trailing)
- −$0.21
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$26.9M
- Diluted EPS
- −$0.25
From the company’s annual report on SEC EDGAR.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Headquarters: New York, United States · 13 employees · sellaslifesciences.com